IsoRay (ISR) Preliminary Q3 Revenue of $1.57 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
IsoRay Announces Preliminary Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Year-over-Year Increase
April 18, 2018 8:30 AM EDTRICHLAND, Wash, April 18, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced preliminary unaudited revenue and gross profit results for the third quarter of fiscal 2018 ended March 31, 2018.
Preliminary revenue and gross profit for the third quarter of fiscal 2018 was as follows:
Preliminary revenue for the three months ended March 31, 2018, was $1.57 million compared to $1.28 million... More